PMID- 20473283
OWN - NLM
STAT- MEDLINE
DCOM- 20101112
LR  - 20231106
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 23
IP  - 8
DP  - 2010 Aug
TI  - ERG rearrangement is specific to prostate cancer and does not occur in any other 
      common tumor.
PG  - 1061-7
LID - 10.1038/modpathol.2010.87 [doi]
AB  - Identification of specific somatic gene alterations is crucial for the insight 
      into the development, progression, and clinical behavior of individual cancer 
      types. The recently discovered recurrent ERG rearrangement in prostate cancer 
      might represent a prostate cancer-specific alteration that has not been 
      systematically assessed in tumors other than prostate cancer. Aim of this study 
      was to assess, whether the ERG rearrangement and the distinct deletion site 
      between TMPRSS2 and ERG, both predominantly resulting in a TMPRSS2-ERG fusion, 
      occur in tumors other than prostate cancer. We assessed 54 different tumor types 
      (2942 samples in total) for their ERG rearrangement status by fluorescence in 
      situ hybridization (FISH). To calibrate, we analyzed 285 prostate cancer samples 
      for the ERG rearrangement frequency. Additionally, we interrogated a 
      high-resolution single nucleotide polymorphism (SNP) data set across 3131 cancer 
      specimens (26 tumor types) for copy number alterations. None of the 54 different 
      tumor types assessed by FISH harbored an ERG rearrangement, whereas the prostate 
      cancer samples revealed an ERG rearrangement in 49.5% of cases. Furthermore, 
      within the 26 tumor types assessed for copy number alterations by SNP, the 
      distinct deletion site between TMPRSS2 and ERG (21q22.2-3) was detectable 
      exclusively in prostate cancer. Although Ewing's sarcoma and AML have known 
      rearrangements rarely involving ERG, we hypothesize that the ERG rearrangement as 
      well as the distinct deletion site on 21q22.2-3 between TMPRSS2 and ERG are 
      prostate-cancer-specific genomic alterations. These observations provide further 
      insight into the oncogenesis of prostate cancer and might be critical for the 
      development of ERG rearrangement assessment as a clinical tool.
FAU - Scheble, Veit J
AU  - Scheble VJ
AD  - Institute of Pathology, Comprehensive Cancer Center, University Hospital of 
      Tuebingen, Tuebingen, Germany.
FAU - Braun, Martin
AU  - Braun M
FAU - Beroukhim, Rameen
AU  - Beroukhim R
FAU - Mermel, Craig H
AU  - Mermel CH
FAU - Ruiz, Christian
AU  - Ruiz C
FAU - Wilbertz, Theresia
AU  - Wilbertz T
FAU - Stiedl, Ann-Cathrin
AU  - Stiedl AC
FAU - Petersen, Karen
AU  - Petersen K
FAU - Reischl, Markus
AU  - Reischl M
FAU - Kuefer, Rainer
AU  - Kuefer R
FAU - Schilling, David
AU  - Schilling D
FAU - Fend, Falko
AU  - Fend F
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Meyerson, Matthew
AU  - Meyerson M
FAU - Rubin, Mark A
AU  - Rubin MA
FAU - Bubendorf, Lukas
AU  - Bubendorf L
FAU - Perner, Sven
AU  - Perner S
LA  - eng
GR  - K08 CA122833/CA/NCI NIH HHS/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100514
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (DNA, Neoplasm)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Adenocarcinoma/*genetics
MH  - DNA Mutational Analysis
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - Gene Deletion
MH  - *Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Oncogene Proteins, Fusion
MH  - Polymorphism, Single Nucleotide
MH  - Prostatic Neoplasms/*genetics
MH  - Serine Endopeptidases
MH  - Tissue Array Analysis
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
PMC - PMC3606550
MID - NIHMS432161
EDAT- 2010/05/18 06:00
MHDA- 2010/11/13 06:00
PMCR- 2013/03/23
CRDT- 2010/05/18 06:00
PHST- 2010/05/18 06:00 [entrez]
PHST- 2010/05/18 06:00 [pubmed]
PHST- 2010/11/13 06:00 [medline]
PHST- 2013/03/23 00:00 [pmc-release]
AID - S0893-3952(22)02665-5 [pii]
AID - 10.1038/modpathol.2010.87 [doi]
PST - ppublish
SO  - Mod Pathol. 2010 Aug;23(8):1061-7. doi: 10.1038/modpathol.2010.87. Epub 2010 May 
      14.